P
REGN icon

Paradiem’s Regeneron Pharmaceuticals REGN Stock Holding History

Paradiem’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,670
Closed -$3.02M – 104
2023
Q1 		$3.02M Buy
3,670
+320
+10% +$241K 0.94% 59
2022
Q4 		$2.42M Sell
3,350
-281
-8% -$207K 0.89% 58
2022
Q3 		$2.5M Buy
+3,631
New +$2.29M 0.97% 58
2021
Q1 		– Sell
-3,313
Closed -$1.71M – 106
2020
Q4 		$1.71M Buy
+3,313
New +$1.79M 0.72% 70

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Paradiem's REGN Position: Q2 2023 in Review

Paradiem sold out of Regeneron Pharmaceuticals (REGN) in Q2 2023, closing a stake of 3,670 shares — an estimated $3.02M sold.

Paradiem first reported a position in REGN in Q4 2020 and held it in 4 quarters. The position peaked at $3.02M in Q1 2023. 1,164 funds tracked by Wall St. Rank hold REGN as of Q2 2023.

  • Paradiem reported no remaining Regeneron Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Paradiem sold 3,670 Regeneron Pharmaceuticals shares in Q2 2023, an estimated $3.02M.
  • Paradiem first reported a position in Regeneron Pharmaceuticals in Q4 2020 and held it in 4 quarters.
  • Paradiem's Regeneron Pharmaceuticals position peaked at $3.02M in Q1 2023.
  • 1,164 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2023.

Based on Paradiem's 13F filing for Q2 2023, filed 18 Jul 2023.